Chemotherapy-induced peripheral neuropathy: A current review

Nathan P Staff, Anna Grisold, Wolfgang Grisold, Anthony John Windebank

Research output: Contribution to journalReview article

61 Citations (Scopus)

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients treated with neurotoxic chemotherapy will develop CIPN, and there is considerable variability in its severity between patients. It is often sensory-predominant with pain and can lead to long-term morbidity in survivors. The prevalence and burden of CIPN late effects will likely increase as cancer survival rates continue to improve. In this review, we discuss the approach to peripheral neuropathy in patients with cancer and address the clinical phenotypes and pathomechanisms of specific neurotoxic chemotherapeutic agents. Ann Neurol 2017;81:772–781.

Original languageEnglish (US)
Pages (from-to)772-781
Number of pages10
JournalAnnals of Neurology
Volume81
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Peripheral Nervous System Diseases
Drug Therapy
Neoplasms
Survivors
Survival Rate
Morbidity
Phenotype
Pain
Therapeutics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Chemotherapy-induced peripheral neuropathy : A current review. / Staff, Nathan P; Grisold, Anna; Grisold, Wolfgang; Windebank, Anthony John.

In: Annals of Neurology, Vol. 81, No. 6, 01.06.2017, p. 772-781.

Research output: Contribution to journalReview article

Staff, Nathan P ; Grisold, Anna ; Grisold, Wolfgang ; Windebank, Anthony John. / Chemotherapy-induced peripheral neuropathy : A current review. In: Annals of Neurology. 2017 ; Vol. 81, No. 6. pp. 772-781.
@article{be81a22ac0854c61b02dd83f03ac6edb,
title = "Chemotherapy-induced peripheral neuropathy: A current review",
abstract = "Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment for cancer. Approximately 30 to 40{\%} of patients treated with neurotoxic chemotherapy will develop CIPN, and there is considerable variability in its severity between patients. It is often sensory-predominant with pain and can lead to long-term morbidity in survivors. The prevalence and burden of CIPN late effects will likely increase as cancer survival rates continue to improve. In this review, we discuss the approach to peripheral neuropathy in patients with cancer and address the clinical phenotypes and pathomechanisms of specific neurotoxic chemotherapeutic agents. Ann Neurol 2017;81:772–781.",
author = "Staff, {Nathan P} and Anna Grisold and Wolfgang Grisold and Windebank, {Anthony John}",
year = "2017",
month = "6",
day = "1",
doi = "10.1002/ana.24951",
language = "English (US)",
volume = "81",
pages = "772--781",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Chemotherapy-induced peripheral neuropathy

T2 - A current review

AU - Staff, Nathan P

AU - Grisold, Anna

AU - Grisold, Wolfgang

AU - Windebank, Anthony John

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients treated with neurotoxic chemotherapy will develop CIPN, and there is considerable variability in its severity between patients. It is often sensory-predominant with pain and can lead to long-term morbidity in survivors. The prevalence and burden of CIPN late effects will likely increase as cancer survival rates continue to improve. In this review, we discuss the approach to peripheral neuropathy in patients with cancer and address the clinical phenotypes and pathomechanisms of specific neurotoxic chemotherapeutic agents. Ann Neurol 2017;81:772–781.

AB - Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients treated with neurotoxic chemotherapy will develop CIPN, and there is considerable variability in its severity between patients. It is often sensory-predominant with pain and can lead to long-term morbidity in survivors. The prevalence and burden of CIPN late effects will likely increase as cancer survival rates continue to improve. In this review, we discuss the approach to peripheral neuropathy in patients with cancer and address the clinical phenotypes and pathomechanisms of specific neurotoxic chemotherapeutic agents. Ann Neurol 2017;81:772–781.

UR - http://www.scopus.com/inward/record.url?scp=85020937133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020937133&partnerID=8YFLogxK

U2 - 10.1002/ana.24951

DO - 10.1002/ana.24951

M3 - Review article

C2 - 28486769

AN - SCOPUS:85020937133

VL - 81

SP - 772

EP - 781

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 6

ER -